Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688628 | 1.00 | POLB (0.39) | POLBMAPK1HTTCYP11B2CYP17A1 | |
| SCHEMBL29688422 | 0.89 | CYP11B1 (0.39) | POLBMAPK1HTTCYP11B2CYP17A1 | |
| SCHEMBL20240859 | 0.89 | CYP11B1 (0.39) | POLBMAPK1HTTCYP11B2CYP17A1 | |
| SCHEMBL30590299 | 0.89 | CYP11B1 (0.39) | POLBMAPK1HTTCYP11B2CYP17A1 | |
| SCHEMBL20240823 | 0.86 | PIK3CD (0.37) | POLBMAPK1HTTCYP11B2CYP17A1 | |
| SCHEMBL29688933 | 0.86 | KDM4E (0.41) | POLBMAPK1HTTCYP11B2CYP17A1 | |
| SCHEMBL20254635 | 0.86 | KDM4E (0.41) | POLBMAPK1HTTCYP11B2CYP17A1 | |
| SCHEMBL29688594 | 0.85 | AKR1C3 (0.44) | CYP11B2PIK3CDCYP11B1 | |
| SCHEMBL20243515 | 0.85 | AKR1C3 (0.44) | CYP11B2PIK3CDCYP11B1 | |
| SCHEMBL28747455 | 0.81 | PIK3CD (0.38) | POLBMAPK1HTTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2023-08-15 | — | — | US | disclosed |
| CN-114805366-A | Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors | 百济神州有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110267959-B | Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors | 百济神州有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-03-31 | — | — | US | disclosed |
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-03-31 | — | — | US | disclosed |
| US-11136323-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2021-10-05 | — | — | US | disclosed |
| US-11136323-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | BEIGENE, LTD. (KY) | 2021-10-05 | — | — | US | disclosed |
| EP-3551630-A1 | IMIDAZO [1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | Beigene, Ltd. (KY) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018103688-A1 | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | BEIGENE, LTD. (KY) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018103688-A1 | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | BEIGENE, LTD. (KY) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098202-A1 | IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS | PIK3CD, PIK3R5, PIK3CA | POLB 1058/4885MAPK1 118/4885HTT 3689/4885 |
| US-11136323-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | POLB 1291/4885MAPK1 125/4885HTT 3445/4885 |
| US-11725012-B2 | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors | PIK3CD, PIK3R5, PIK3CA | POLB 1277/4885MAPK1 110/4885HTT 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.